314 related articles for article (PubMed ID: 31292389)
1. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab.
Tabata S; Higuchi T; Tatsukawa S; Narimatsu K; Takeo H; Matsukuma S; Ito T
Intern Med; 2019 Nov; 58(22):3313-3318. PubMed ID: 31292389
[TBL] [Abstract][Full Text] [Related]
2. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717
[TBL] [Abstract][Full Text] [Related]
3. Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab.
Iskandar A; Hwang A; Dasanu CA
J Oncol Pharm Pract; 2019 Dec; 25(8):2016-2018. PubMed ID: 30486744
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy.
Yuzuriha A; Saitoh T; Koiso H; Mitsui T; Uchiumi H; Yokohama A; Handa H; Kojima M; Tsukamoto N; Karaswa M; Murakami H; Nojima Y
Acta Haematol; 2011; 126(3):147-50. PubMed ID: 21757886
[TBL] [Abstract][Full Text] [Related]
5. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
6. Membranous nephropathy with thrombotic microangiopathy-like lesions successfully treated with tocilizumab in a patient with idiopathic multicentric Castleman disease.
Tosaki T; Okabe M; Suzuki T; Shimizu A; Koike K; Tsuboi N; Kawamura T; Ohashi R; Yano S; Yokoo T
CEN Case Rep; 2021 May; 10(2):265-272. PubMed ID: 33389670
[TBL] [Abstract][Full Text] [Related]
7. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic multicentric Castleman disease with Sjögren's syndrome and secondary membranous nephropathy: a case report and review of the literature.
Pan Y; Cui Z; Wang S; Zheng D; Deng Z; Tian X; Guo H; Bao W; Zhou S; Wang Y
BMC Nephrol; 2020 Dec; 21(1):528. PubMed ID: 33276741
[TBL] [Abstract][Full Text] [Related]
9. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment with tocilizumab for refractory anemia and slowly progressive renal glomerulosclerosis in multicentric Castleman disease: A case report.
Sugawara E; Sato T; Amasaki Y; Katsumata K
Medicine (Baltimore); 2022 Feb; 101(8):e28941. PubMed ID: 35212301
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
12. Splenectomy induced complete remission in a patient with multicentric Castleman's disease and autoimmune hemolytic anemia.
Lerza R; Castello G; Truini M; Ballarino P; Tredici S; Cavallini D; Pannacciulli I
Ann Hematol; 1999 Apr; 78(4):193-6. PubMed ID: 10348152
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with rituximab of an infant with refractory autoimmune hemolytic anemia.
Moriya K; Matsuhashi T; Onuma M; Niizuma H; Rikiishi T; Asada H; Suzuki J; Sasahara Y; Kure S
Int J Hematol; 2013 Aug; 98(2):237-9. PubMed ID: 23702915
[TBL] [Abstract][Full Text] [Related]
14. Fatal fulminant hemolysis-associated pulmonary embolism in mixed-type autoimmune hemolytic anemia: A case report.
Imataki O; Iseki K; Uchida S; Uemura M; Kadowaki N
Medicine (Baltimore); 2020 Feb; 99(6):e18984. PubMed ID: 32028408
[TBL] [Abstract][Full Text] [Related]
15. [Autoimmune hemolytic anemia in a patient with idiopathic interstitial pneumonia].
Fukuda K; Yokoyama Y; Kamada Y; Taoka K; Suzukawa K; Chiba S
Rinsho Ketsueki; 2011 Jan; 52(1):14-7. PubMed ID: 21378476
[TBL] [Abstract][Full Text] [Related]
16. Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.
Arakawa A; Iizuka M; Matsuda S; Matsubara E; Yamazaki H; Yoshikawa N; Tanaka H; Yoshizawa T
Intern Med; 2021 Dec; 60(24):3995-3998. PubMed ID: 34219105
[TBL] [Abstract][Full Text] [Related]
17. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
Pamuk GE; Turgut B; Demir M; Tezcan F; Vural O
Am J Hematol; 2006 Aug; 81(8):631-3. PubMed ID: 16906592
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
Herishanu Y; Levi S; Kamdjou T; Bornstein Y; Ram R; Benyamini N; Varon D; Avivi I; Perry C
Br J Haematol; 2021 Jan; 192(1):e1-e4. PubMed ID: 33095444
[No Abstract] [Full Text] [Related]
19. Rituximab as a First-line Treatment for Autoimmune Hemolytic Anemia in Multicentric Castleman's Disease.
Cáceres Medina JL; González Torres LA; Gamboa-Meza A; Cantu-Rodriguez OG
Cureus; 2024 Apr; 16(4):e59080. PubMed ID: 38800203
[TBL] [Abstract][Full Text] [Related]
20. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
